This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 89/6/477    most recent hh1801.097034v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, I. Articles by Koh, G. Y. Search for Related Content PubMed PubMed Citation Articles by Kim, I. Articles by Koh, G. Y. Pubmed/NCBI databases Substance via MeSH Related Collections Angiogenesis Endothelium/vascular type/nitric oxide Mechanism of atherosclerosis/growth factors Other Vascular biology

(Circulation Research. 2001;89:477.)
© 2001 American Heart Association, Inc.

Reports

Angiopoietin-1 Reduces VEGF-Stimulated Leukocyte Adhesion to Endothelial Cells by Reducing ICAM-1, VCAM-1, and E-Selectin Expression

Injune Kim, Sang-Ok Moon, Sung Kwang Park, Soo Wan Chae, Gou Young Koh

From the National Creative Research Initiatives Center for Endothelial Cells (I.K., S.O.M., G.Y.K.) and Departments of Internal Medicine (S.K.P.) and Pharmacology (S.W.C.), Chonbuk National University School of Medicine, Chonju, Republic of Korea.

Correspondence to Gou Young Koh, MD, PhD, National Creative Research >Initiatives Center for Endothelial Cells, Department of Life Science, Pohang University of Science and Technology, San 31, Hyoja-Dong, Pohang, 790-784, Republic of Korea. E-mail gykoh{at}postech.ac.kr

Abstract

Vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang1) are potent vasculogenic and angiogenic factors that hold promise as a means to produce therapeutic vascularization and angiogenesis. However, VEGF also acts as a proinflammatory cytokine by inducing adhesion molecules that bind leukocytes to endothelial cells, an initial and essential step toward inflammation. In the present study, we used human umbilical vascular endothelial cells (HUVECs) to examine the effect of Ang1 on VEGF-induced expression of three adhesion molecules: intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin. Interestingly, Ang1 suppressed VEGF-induced expression of these adhesion molecules. Furthermore, Ang1 reduced VEGF-induced leukocyte adhesion to HUVECs. These results demonstrate that Ang1 counteracts VEGF-induced inflammation by reducing VEGF-induced endothelial adhesiveness.

Key Words: vascular endothelial growth factor • angiopoietin • adhesion • inflammation

Two endothelial cell–specific growth factors, vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang1), act cooperatively and interactively during prenatal and postnatal vascular development.¹ In fact, co-overexpression of VEGF and Ang1 in mouse skin or rabbit ischemic hindlimb produces an additive increase in vessel formation.^2,3 Although overexpression of VEGF alone in mouse skin produced profound angiogenesis, it also produced enhanced leukocyte rolling and adhesion, vascular leakage, and inflammation.^2,4 Thus, VEGF is also a proinflammatory cytokine in addition to being an angiogenic factor. However, co-overexpression of VEGF and Ang1 in mouse skin showed less vascular leakage and inflammation compared with VEGF alone.² These data clearly indicate that Ang1 counteracts some subset of activities of VEGF in endothelial cells.

We recently demonstrated that VEGF stimulates the expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin mRNAs in endothelial cells through the Flk-1/KDR receptor.⁵ This stimulation is mediated through nuclear factor-B (NF-B) activation and is suppressed by phosphatidylinositol (PI) 3'-kinase.⁵ Other studies have shown that Ang1 strongly activates the PI 3'-kinase/Akt pathway in endothelial cells through its binding to the Tie2 receptor.^6,7 Therefore, in this study, we assessed the specific role of Ang1 in VEGF-induced expression of adhesion molecules in endothelial cells. Interestingly, our results indicate that Ang1 counteracts VEGF-induced expression and activity of adhesion molecules.

Materials and Methods

Ang1*, rTie1-Fc, and rTie2-Fc were obtained from Regeneron Pharmaceuticals, Inc. Ang1* is a recombinant version of Ang1. Recombinant human VEGF₁₆₅ was purchased from R&D Systems. Human umbilical vascular endothelial cells (HUVECs) were prepared and maintained as previously described.⁶

RNase protection assay (RPA), Western blot analyses, and flow cytometric analyses for human ICAM-1, VCAM-1, and E-selectin were performed as previously described.⁵ Leukocyte-endothelial adhesion was measured as previously described.⁵

All signals were visualized and analyzed by densitometric scanning (LAS-1000, Fuji Film). Data are expressed as mean±SD. Statistical significance was tested using 1-way ANOVA followed by the Student-Newman-Keuls test. Statistical significance was set at P<0.05.

An expanded Materials and Methods section can be found in the online data supplement available at http://www.circresaha.org.

Results and Discussion

We developed a method of RPA by which we can simultaneously detect the mRNA levels of ICAM-1, VCAM-1, E-selectin, and cyclophilin. Because VEGF produces a maximum effect at 4 hours on expression of these adhesion molecules,⁵ we examined the effect of VEGF at this time point. VEGF stimulated expression of these adhesion molecules in a dose-dependent manner (Figure 1A). Ang1 (200 ng/mL) inhibited 23% to 29%, 46% to 48%, and 62% to 68% of the VEGF-induced ICAM-1, VCAM-1, and E-selectin mRNAs, respectively, at 4 hours and 6 hours, whereas Ang1 (200 ng/mL) by itself did not produce any significant effect on mRNA levels of these adhesion molecules (Figure 1B). A 5-fold molar excess of rTie2-Fc, but not rTie1-Fc, mostly blocked Ang1-induced suppression of VEGF-induced mRNA of adhesion molecules (Figure 1C). These results indicate that Ang1 exerts its effects on endothelial cells through mainly Tie2 receptor binding, but not through Tie1.

View larger version (55K): [in this window] [in a new window]   Figure 1. Ang1 suppresses VEGF-induced mRNA levels of ICAM-1, VCAM-1, and E-selectin in HUVECs. A, HUVECs were incubated for 4 hours with the indicated dose of VEGF165. Yeast total RNA (10 µg) was similarly assayed in the presence of RNase (T). To clarify the identity of the bands, ICAM-1 (I), VCAM-1 (V), and E-selectin (E) probes were applied individually to the total RNA from HUVECs treated with VEGF for 4 hours to reveal protected bands of 367, 279, and 187 bp, respectively. B, HUVECs were incubated for 4 hours and 6 hours with control buffer (CB), Ang1 (A1, 200 ng/mL), VEGF165 (VE, 20 ng/mL), or Ang1 plus VEGF165 (AV). C, HUVECs were incubated for 4 hours with control buffer (CB), Ang1 (A1, 200 ng/mL), VEGF165 (VE, 20 ng/mL), or Ang1 plus VEGF165 (AV) with or without 5-fold molar excess of rTie2-Fc (T2) or rTie1-Fc (T1). D, HUVECs were incubated for 4 hours with control buffer (CB), wortmannin (WT, 30 nmol/L), VEGF165 (VE, 20 ng/mL), wortmannin plus VEGF165 (WV), Ang1 plus VEGF165 (AV), or Ang1 plus VEGF165 plus wortmannin (AVW). Total RNAs (10 µg) were subjected to multiplex RPA probed with 4 antisense RNAs: ICAM-1, VCAM-1, E-selectin, and cyclophilin. Bottom panels, Densitometric analyses are presented as the relative ratio of ICAM-1, VCAM-1, or E-selectin mRNA to cyclophilin mRNA. The relative ratio measured in the CB is arbitrarily presented as 1. Bars represent the mean±SD from 4 experiments. *P<0.05 vs 0 ng/mL of VEGF165 or CB; +P<0.05 vs VE; and #P<0.05 vs AV.

We previously demonstrated that VEGF stimulated the expression of ICAM-1, VCAM-1, and E-selectin mRNAs mainly through activation of phospholipase-C and NF-B.⁵ This induction was suppressed by activation of PI 3'-kinase.⁵ Because Ang1 is a strong activator of the intracellular PI 3'-kinase/Akt signaling system,^6,7 Ang1-induced activation of PI 3'-kinase/Akt could be the main pathway for suppressing the VEGF-induced expression of adhesion molecules. As we expected, suppression of basal PI 3'-kinase by the pharmacological inhibitor wortmannin (30 nmol/L) induced expression of adhesion molecules (Figure 1D). Furthermore, addition of wortmannin (30 nmol/L) not only enhanced VEGF-induced expression of adhesion molecules but also reversed Ang1-induced suppressive effect on VEGF-induced expression of adhesion molecules (Figure 1D). Addition of another PI 3'-kinase inhibitor, LY294002 (100 nmol/L), produced the same results (data not shown). In fact, our preliminary results indicated that selective activation (or inactivation) of PI 3'-kinase/Akt using adenoviral transfer reduced (or enhanced) VEGF-induced expression of adhesion molecules (data not shown). Thus, Ang1 counteracts VEGF-induced expression of these adhesion molecules, possibly through activation of the PI 3'-kinase/Akt pathway.

We looked further at the protein levels of ICAM-1, VCAM-1, and E-selectin in HUVECs treated with Ang1 and VEGF. Consistent with the RPA data, Ang1 (200 ng/mL) by itself did not produce any significant effect, whereas VEGF (20 ng/mL) increased protein levels at 6 hours (Figure 2). Addition of Ang1 (200 ng/mL) inhibited 43%, 44%, and 62% of the VEGF-induced ICAM-1, VCAM-1, and E-selectin protein levels (Figure 2). Using flow cytometry, we also confirmed that Ang1 inhibited VEGF-induced expression of these adhesion molecules on the cell surface of HUVECs (data not shown).

View larger version (53K): [in this window] [in a new window]   Figure 2. Ang1 suppresses VEGF-induced protein levels of ICAM-1, VCAM-1, and E-selectin in HUVECs. HUVECs were incubated for 6 hours with control buffer (CB), Ang1 (A1, 200 ng/mL), VEGF165 (VE, 20 ng/mL), or Ang1 plus VEGF165 (AV). Each lane contains 50 µg of total protein from the cells. A through C, Western blots were probed with appropriate antibody (top panels). The blots were reprobed with an anti–actin antibody (bottom panels). D, Densitometric analyses are presented as the relative ratio of ICAM-1:actin, VCAM-1:actin, and E-selectin:actin. The relative ratio in the CB is arbitrarily presented as 1. Bars represent the mean±SD from 5 experiments. *P<0.05 vs CB; +P<0.05 vs VE.

Because the induction of adhesion molecules in endothelial cells induces leukocyte adhesion, we examined whether Ang1 reduces VEGF-induced leukocyte adhesion to HUVECs. Ang1 (200 ng/mL) by itself did not produce any effect, whereas VEGF (20 ng/mL) produced an increase of 2.8-fold in leukocyte adhesion after 8 hours compared with addition of control buffer (Figure 3). Ang1 (200 ng/mL) reduced 46% of the VEGF-induced leukocyte adhesion (Figure 3). A 5-fold molar excess of rTie2-Fc, but not rTie1-Fc, completely blocked Ang1-induced suppression of VEGF-induced leukocyte adhesion (Figure 3). These results indicate that Ang1 exerts its effects in endothelial cells through Tie2 receptor binding. Function-blocking antibodies to ICAM-1, VCAM-1, and E-selectin, either singly or as a triple combination, suppressed VEGF-induced leukocyte adhesion to varying extents (Figure 3). These data suggest that VEGF-induced adhesiveness requires combined activity of each of these adhesion molecules, because inhibition of the individual molecules could not completely impair the effects of VEGF.

View larger version (56K): [in this window] [in a new window]   Figure 3. Ang1 suppresses VEGF-induced HUVEC adhesiveness. A, Representative phase-contrast photographs of leukocyte adhesion to HUVECs. Note that there are more leukocytes in HUVECs treated with VEGF than in those treated with control buffer (CB), Ang1, or Ang1 plus VEGF (A+V). Bar=50 µm. B, Quantification of the leukocyte adhesion to HUVECs. Leukocytes were labeled with Vybrant DiD (Molecular Probes) and added to confluent monolayers of HUVECs, which were treated with and without VEGF165 (20 ng/mL) for 8 hours and were also treated with CB, Ang1 (A1, 200 ng/mL) with or without 5-fold molar excess of rTie2-Fc (Tie2) or rTie1-Fc (Tie1), and anti–ICAM-1 antibody (IA, 10 µg/mL), anti–VCAM-1 antibody (VA, 10 µg/mL), anti–E-selectin antibody (SA, 10 µg/mL), or a triple combination of these antibodies (TA). Then, leukocyte adhesion was measured as described in Materials and Methods. Bars represent the mean±SD from 5 experiments. *P<0.05 vs CB; +P<0.05 vs CB plus VEGF165 (20 ng/mL).

To our knowledge, these results are the first to demonstrate that Ang1 can suppress the expression of adhesion molecules. Furthermore, a recent in vitro experiment demonstrated that Ang1 decreases basal and VEGF-induced endothelial permeability.⁸ Taken together, Ang1 counteracts VEGF-induced inflammation in endothelial cells while having an additive effect on vessel formation.^2,3 Therefore, combined treatment with VEGF and Ang1 could be better than sole treatment with one for enhancing therapeutic vascularization and angiogenesis while avoiding inflammation.

Acknowledgments

This work was supported by the Creative Research Initiatives of the Korean Ministry of Science and Technology. We thank Drs John S. Rudge and George D. Yancopoulos for enthusiastic support and for providing angiopoietin- and Tie-related reagents.

Received March 13, 2001; accepted July 31, 2001.

References

1. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. . 2000; 407: 242–248.

2. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. . 1999; 286: 2511–2514.

3. Chae JK, Kim I, Lim ST, Chung MJ, Kim WH, Kim HG, Ko JK, Koh GY. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol. . 2000; 20: 2573–2578.

4. Detmar M, Brown LF, Schon MP, Elicker BM, Velasco P, Richard L, Fukumura D, Monsky W, Claffey KP, Jain RK. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol. . 1998; 111: 1–6.

5. Kim I, Moon S-O, Kim SH, Kim HJ, Koh YS, Koh GY. VEGF stimulates expression of ICAM-1, VCAM-1 and E-selectin through nuclear factor-B activation in endothelial cells. J Biol Chem. . 2001; 276: 7614–7620.

6. Kim I, Kim HG, So J-N, Kim JH, Kwak HJ, Koh GY. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3`-kinase/Akt signal transduction pathway. Circ Res. . 2000; 86: 24–29.

7. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O’Connor DS, Li F, Altieri DC, Sessa WC. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem. . 2000; 275: 9102–9105.

8. Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, Rudge J, Yancopoulos G, Vadas MA. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res. . 2000; 87: 603–607.

This article has been cited by other articles:

				I. Mack, R. S. BelAiba, T. Djordjevic, A. Gorlach, H. Hauner, and B. L. Bader Functional analyses reveal the greater potency of preadipocytes compared with adipocytes as endothelial cell activator under normoxia, hypoxia, and TNF{alpha} exposure Am J Physiol Endocrinol Metab, September 1, 2009; 297(3): E735 - E748. [Abstract] [Full Text] [PDF]

				T. E. Walshe, V. S. Dole, A. S.R. Maharaj, I. S. Patten, D. D. Wagner, and P. A. D'Amore Inhibition of VEGF or TGF-{beta} Signaling Activates Endothelium and Increases Leukocyte Rolling Arterioscler Thromb Vasc Biol, August 1, 2009; 29(8): 1185 - 1192. [Abstract] [Full Text] [PDF]

				H. T. Yuan, E. V. Khankin, S. A. Karumanchi, and S. M. Parikh Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium Mol. Cell. Biol., April 15, 2009; 29(8): 2011 - 2022. [Abstract] [Full Text] [PDF]

				M van der Heijden, G P van Nieuw Amerongen, P Koolwijk, V W M van Hinsbergh, and A B J Groeneveld Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients Thorax, October 1, 2008; 63(10): 903 - 909. [Abstract] [Full Text] [PDF]

				S. Lee, W. Kim, D. H. Kim, S.-O. Moon, Y. J. Jung, A. S. Lee, K. P. Kang, K. Y. Jang, S. Y. Lee, M. J. Sung, et al. Protective effect of COMP-angiopoietin-1 on cyclosporine-induced renal injury in mice Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2784 - 2794. [Abstract] [Full Text] [PDF]

				D. Voskas, Y. Babichev, L. S. Ling, J. Alami, Y. Shaked, R. S. Kerbel, B. Ciruna, and D. J. Dumont An eosinophil immune response characterizes the inflammatory skin disease observed in Tie-2 transgenic mice J. Leukoc. Biol., July 1, 2008; 84(1): 59 - 67. [Abstract] [Full Text] [PDF]

				D. C. M. Simoes, T. Vassilakopoulos, D. Toumpanakis, K. Petrochilou, C. Roussos, and A. Papapetropoulos Angiopoietin-1 Protects against Airway Inflammation and Hyperreactivity in Asthma Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1314 - 1321. [Abstract] [Full Text] [PDF]

				M. Mofarrahi, T. Nouh, S. Qureshi, L. Guillot, D. Mayaki, and S. N. A. Hussain Regulation of angiopoietin expression by bacterial lipopolysaccharide Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L955 - L963. [Abstract] [Full Text] [PDF]

				R. Maliba, A. Brkovic, P.-E. Neagoe, L. R. Villeneuve, and M. G. Sirois Angiopoietin-mediated endothelial P-selectin translocation: cell signaling mechanisms J. Leukoc. Biol., February 1, 2008; 83(2): 352 - 360. [Abstract] [Full Text] [PDF]

				T. Mammoto, S. M. Parikh, A. Mammoto, D. Gallagher, B. Chan, G. Mostoslavsky, D. E. Ingber, and V. P. Sukhatme Angiopoietin-1 Requires p190 RhoGAP to Protect against Vascular Leakage in Vivo J. Biol. Chem., August 17, 2007; 282(33): 23910 - 23918. [Abstract] [Full Text] [PDF]

				W. S.N. Shim, I. A.W. Ho, and P. E.H. Wong Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis Mol. Cancer Res., July 1, 2007; 5(7): 655 - 665. [Abstract] [Full Text] [PDF]

				J. H. Chidlow Jr., D. Shukla, M. B. Grisham, and C. G. Kevil Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G5 - G18. [Abstract] [Full Text] [PDF]

				S. D. McCarter, S. H. J. Mei, P. F. H. Lai, Q. W. Zhang, C. H. Parker, R. S. Suen, R. D. Hood, Y. D. Zhao, Y. Deng, R. N. N. Han, et al. Cell-based Angiopoietin-1 Gene Therapy for Acute Lung Injury Am. J. Respir. Crit. Care Med., May 15, 2007; 175(10): 1014 - 1026. [Abstract] [Full Text] [PDF]

				A. K. Stannard, R. Khurana, I. M. Evans, V. Sofra, D. I.R. Holmes, and I. Zachary Vascular Endothelial Growth Factor Synergistically Enhances Induction of E-Selectin by Tumor Necrosis Factor-{alpha} Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 494 - 502. [Abstract] [Full Text] [PDF]

				S. Lee, W. Kim, S.-O. Moon, M. J. Sung, D. H. Kim, K. P. Kang, K. Y. Jang, S. Y. Lee, B. H. Park, G. Y. Koh, et al. Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes Nephrol. Dial. Transplant., February 1, 2007; 22(2): 396 - 408. [Abstract] [Full Text] [PDF]

				L. Ye, H. Kh. Haider, S. Jiang, R. S. Tan, R. Ge, P. K. Law, and E. K.W. Sim Improved angiogenic response in pig heart following ischaemic injury using human skeletal myoblast simultaneously expressing VEGF165 and angiopoietin-1 Eur J Heart Fail, January 1, 2007; 9(1): 15 - 22. [Abstract] [Full Text] [PDF]

				D. Pfaff, U. Fiedler, and H. G. Augustin Emerging roles of the Angiopoietin-Tie and the ephrin-Eph systems as regulators of cell trafficking J. Leukoc. Biol., October 1, 2006; 80(4): 719 - 726. [Abstract] [Full Text] [PDF]

				R. Harfouche and S. N. A. Hussain Signaling and regulation of endothelial cell survival by angiopoietin-2 Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1635 - H1645. [Abstract] [Full Text] [PDF]

				J. Herrmann, L. O. Lerman, D. Mukhopadhyay, C. Napoli, and A. Lerman Angiogenesis in Atherogenesis Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 1948 - 1957. [Abstract] [Full Text] [PDF]

				W. Kim, S.-O. Moon, S. Y. Lee, K. Y. Jang, C.-H. Cho, G. Y. Koh, K.-S. Choi, K.-H. Yoon, M. J. Sung, D. H. Kim, et al. COMP-Angiopoietin-1 Ameliorates Renal Fibrosis in a Unilateral Ureteral Obstruction Model J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2474 - 2483. [Abstract] [Full Text] [PDF]

				A. I. Nykanen, K. Pajusola, R. Krebs, M. A.I. Keranen, O. Raisky, P. K. Koskinen, K. Alitalo, and K. B. Lemstrom Common Protective and Diverse Smooth Muscle Cell Effects of AAV-Mediated Angiopoietin-1 and -2 Expression in Rat Cardiac Allograft Vasculopathy Circ. Res., June 9, 2006; 98(11): 1373 - 1380. [Abstract] [Full Text] [PDF]

				S. D. McCarter, P. F. H. Lai, R. S. Suen, and D. J. Stewart Regulation of Endothelin-1 by Angiopoietin-1: Implications for Inflammation. Experimental Biology and Medicine, June 1, 2006; 231(6): 985 - 991. [Abstract] [Full Text] [PDF]

				I. Kalomenidis, A. Kollintza, I. Sigala, A. Papapetropoulos, S. Papiris, R. W. Light, and C. Roussos Angiopoietin-2 Levels Are Elevated in Exudative Pleural Effusions Chest, May 1, 2006; 129(5): 1259 - 1266. [Abstract] [Full Text] [PDF]

				N. P.J. Brindle, P. Saharinen, and K. Alitalo Signaling and Functions of Angiopoietin-1 in Vascular Protection Circ. Res., April 28, 2006; 98(8): 1014 - 1023. [Abstract] [Full Text] [PDF]

				R. Braren, H. Hu, Y. H. Kim, H. E. Beggs, L. F. Reichardt, and R. Wang Endothelial FAK is essential for vascular network stability, cell survival, and lamellipodial formation J. Cell Biol., January 3, 2006; 172(1): 151 - 162. [Abstract] [Full Text] [PDF]

				D. Mehta and A. B. Malik Signaling Mechanisms Regulating Endothelial Permeability Physiol Rev, January 1, 2006; 86(1): 279 - 367. [Abstract] [Full Text] [PDF]

				F. Baffert, T. Le, G. Thurston, and D. M. McDonald Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H107 - H118. [Abstract] [Full Text] [PDF]

				F. Roviezzo, S. Tsigkos, A. Kotanidou, M. Bucci, V. Brancaleone, G. Cirino, and A. Papapetropoulos Angiopoietin-2 Causes Inflammation in Vivo by Promoting Vascular Leakage J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 738 - 744. [Abstract] [Full Text] [PDF]

				J.-K. Min, Y.-M. Kim, S. W. Kim, M.-C. Kwon, Y.-Y. Kong, I. K. Hwang, M. H. Won, J. Rho, and Y.-G. Kwon TNF-Related Activation-Induced Cytokine Enhances Leukocyte Adhesiveness: Induction of ICAM-1 and VCAM-1 via TNF Receptor-Associated Factor and Protein Kinase C-Dependent NF-{kappa}B Activation in Endothelial Cells J. Immunol., July 1, 2005; 175(1): 531 - 540. [Abstract] [Full Text] [PDF]

				D. Jho, D. Mehta, G. Ahmmed, X.-P. Gao, C. Tiruppathi, M. Broman, and A. B. Malik Angiopoietin-1 Opposes VEGF-Induced Increase in Endothelial Permeability by Inhibiting TRPC1-Dependent Ca2 Influx Circ. Res., June 24, 2005; 96(12): 1282 - 1290. [Abstract] [Full Text] [PDF]

				C. C. Weber, H. Cai, M. Ehrbar, H. Kubota, G. Martiny-Baron, W. Weber, V. Djonov, E. Weber, A. S. Mallik, M. Fussenegger, et al. Effects of Protein and Gene Transfer of the Angiopoietin-1 Fibrinogen-like Receptor-binding Domain on Endothelial and Vessel Organization J. Biol. Chem., June 10, 2005; 280(23): 22445 - 22453. [Abstract] [Full Text] [PDF]

				K.-T. Kim, H.-H. Choi, M. O. Steinmetz, B. Maco, R. A. Kammerer, S. Y. Ahn, H.-Z. Kim, G. M. Lee, and G. Y. Koh Oligomerization and Multimerization Are Critical for Angiopoietin-1 to Bind and Phosphorylate Tie2 J. Biol. Chem., May 20, 2005; 280(20): 20126 - 20131. [Abstract] [Full Text] [PDF]

				C. Lemieux, R. Maliba, J. Favier, J.-F. Theoret, Y. Merhi, and M. G. Sirois Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses Blood, February 15, 2005; 105(4): 1523 - 1530. [Abstract] [Full Text] [PDF]

				N. Kilic, L. Oliveira-Ferrer, J.-H. Wurmbach, S. Loges, F. Chalajour, S. N. Vahid, J. Weil, M. Fernando, and S. Ergun Pro-angiogenic Signaling by the Endothelial Presence of CEACAM1 J. Biol. Chem., January 21, 2005; 280(3): 2361 - 2369. [Abstract] [Full Text] [PDF]

				B. Witzenbichler, D. Westermann, S. Knueppel, H.-P. Schultheiss, and C. Tschope Protective Role of Angiopoietin-1 in Endotoxic Shock Circulation, January 4, 2005; 111(1): 97 - 105. [Abstract] [Full Text] [PDF]

				H. S. Lim, A. D. Blann, A. Y. Chong, B. Freestone, and G. Y.H. Lip Plasma Vascular Endothelial Growth Factor, Angiopoietin-1, and Angiopoietin-2 in Diabetes: Implications for cardiovascular risk and effects of multifactorial intervention Diabetes Care, December 1, 2004; 27(12): 2918 - 2924. [Abstract] [Full Text] [PDF]

				B. A. Hesser, X. H. Liang, G. Camenisch, S. Yang, D. A. Lewin, R. Scheller, N. Ferrara, and H.-P. Gerber Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells Blood, July 1, 2004; 104(1): 149 - 158. [Abstract] [Full Text] [PDF]

				C.-H. Cho, R. A. Kammerer, H. J. Lee, M. O. Steinmetz, Y. S. Ryu, S. H. Lee, K. Yasunaga, K.-T. Kim, I. Kim, H.-H. Choi, et al. COMP-Ang1: A designed angiopoietin-1 variant with nonleaky angiogenic activity PNAS, April 13, 2004; 101(15): 5547 - 5552. [Abstract] [Full Text] [PDF]

				B. M. Hosking, S.-C. M. Wang, M. Downes, P. Koopman, and G. E. O. Muscat The VCAM-1 Gene That Encodes the Vascular Cell Adhesion Molecule Is a Target of the Sry-related High Mobility Group Box Gene, Sox18 J. Biol. Chem., February 13, 2004; 279(7): 5314 - 5322. [Abstract] [Full Text] [PDF]

				S. H. Rudolfsson, P. Wikstrom, A. Jonsson, O. Collin, and A. Bergh Hormonal Regulation and Functional Role of Vascular Endothelial Growth Factor A in the Rat Testis Biol Reprod, February 1, 2004; 70(2): 340 - 347. [Abstract] [Full Text] [PDF]

				K. G. Peters, C. D. Kontos, P. C. Lin, A. L. Wong, P. Rao, L. Huang, M. W. Dewhirst, and S. Sankar Functional Significance of Tie2 Signaling in the Adult Vasculature Recent Prog. Horm. Res., January 1, 2004; 59(1): 51 - 71. [Abstract] [Full Text]

				H. Ju, D. J. Behm, S. Nerurkar, M. E. Eybye, R. E. Haimbach, A. R. Olzinski, S. A. Douglas, and R. N. Willette p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 1. p38 MAPK-Dependent Endothelial Dysfunction and Hypertension J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 932 - 938. [Abstract] [Full Text] [PDF]

				S. H. Rudolfsson, A. Johansson, I. Franck Lissbrant, P. Wikstrom, and A. Bergh Localized Expression of Angiopoietin 1 and 2 May Explain Unique Characteristics of the Rat Testicular Microvasculature Biol Reprod, October 1, 2003; 69(4): 1231 - 1237. [Abstract] [Full Text] [PDF]

				A. R. Hess, E. A. Seftor, R. E. B. Seftor, and M. J. C. Hendrix Phosphoinositide 3-Kinase Regulates Membrane Type 1-Matrix Metalloproteinase (MMP) and MMP-2 Activity during Melanoma Cell Vasculogenic Mimicry Cancer Res., August 15, 2003; 63(16): 4757 - 4762. [Abstract] [Full Text] [PDF]

				W. Kim, S.-O. Moon, S. Lee, M. J. Sung, S. H. Kim, and S. K. Park Adrenomedullin Reduces VEGF-Induced Endothelial Adhesion Molecules and Adhesiveness Through a Phosphatidylinositol 3'-Kinase Pathway Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1377 - 1383. [Abstract] [Full Text] [PDF]

				B. H. Jeon, F. Khanday, S. Deshpande, A. Haile, M. Ozaki, and K. Irani Tie-ing the Antiinflammatory Effect of Angiopoietin-1 to Inhibition of NF-{kappa}B Circ. Res., April 4, 2003; 92(6): 586 - 588. [Full Text] [PDF]

				D. P. Hughes, M. B. Marron, and N. P.J. Brindle The Antiinflammatory Endothelial Tyrosine Kinase Tie2 Interacts With a Novel Nuclear Factor-{kappa}B Inhibitor ABIN-2 Circ. Res., April 4, 2003; 92(6): 630 - 636. [Abstract] [Full Text] [PDF]

				N. Anim-Nyame, J. Gamble, S. R. Sooranna, M. R. Johnson, and P. J. Steer Microvascular permeability is related to circulating levels of tumour necrosis factor-{alpha} in pre-eclampsia Cardiovasc Res, April 1, 2003; 58(1): 162 - 169. [Abstract] [Full Text] [PDF]

				A. I. Nykanen, R. Krebs, A. Saaristo, P. Turunen, K. Alitalo, S. Yla-Herttuala, P. K. Koskinen, and K. B. Lemstrom Angiopoietin-1 Protects Against the Development of Cardiac Allograft Arteriosclerosis Circulation, March 11, 2003; 107(9): 1308 - 1314. [Abstract] [Full Text] [PDF]

				T.-H. Lee, H. K. Avraham, S. Jiang, and S. Avraham Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability J. Biol. Chem., February 7, 2003; 278(7): 5277 - 5284. [Abstract] [Full Text] [PDF]

				J. T. Rosenbaum Sugar Creates a Sticky Business: Round Up the Usual Suspects Am. J. Pathol., May 1, 2002; 160(5): 1547 - 1550. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 89/6/477    most recent hh1801.097034v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, I. Articles by Koh, G. Y. Search for Related Content PubMed PubMed Citation Articles by Kim, I. Articles by Koh, G. Y. Pubmed/NCBI databases Substance via MeSH Related Collections Angiogenesis Endothelium/vascular type/nitric oxide Mechanism of atherosclerosis/growth factors Other Vascular biology